Clinical trial · Observational
Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease
Time of Treatment With Low Molecular Weight Heparins in Cancer Patients With Thromboembolic Disease. Procoagulant Role of Phospholipid-dependent Microparticles.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer is the most important acquired risk factor of thromboembolisms. More than 20% of all episodes of venous thromboembolism (VT) or pulmonary thromboembolisms (PT) are cancer related. Cancer patients with VT or PT are treated with low molecular weight heparins (LMWH) during at least 3 months, but nowadays the duration of treatment is not accurately determined. The D-Dimer determination has been used like recurrence predictors after LMWH treatment suspension, but in cancer patients the useful is limited. Phospholipid-dependent microparticles could been used like recurrence predictors in cancer patients and tailored the duration of LMWH treatment for each patient.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Pulmonary Thromboembolisms | — | UNRESOLVED | — |
| Venous Thromboembolism | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Recurrence thromboembolisms
- timeFrame
- 3 months
- description
- Venous thromboembolisms or Pulmonary thromboembolism recurrence after LMWH suppression
- measure
- Recurrence thromboembolisms
- timeFrame
- 6 months
- description
- Venous thromboembolisms or Pulmonary thromboembolism recurrence after LMWH suppression
Secondary outcomes (2)
- measure
- Hemorrhagic events
- timeFrame
- 6 months
- description
- Hemorrhagic events due to LMWH treatment
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with diagnosis of cancer (any) and diagnosis of pulmonary thromboembolism (PT) or venous thromboembolism (VT) , in treatment with low molecular weight heparin (LMWH). * Patients treated with LMWH since cancer diagnostic. * Signed informed consent sheet Exclusion Criteria: * Patients with life expectancy lower than 6 months * Pregnancy woman * Patients with cerebral metastasis
References
Publications (0)
Data not yet available